Are new weight loss drugs an answer or problem?
World of DTC Marketing
JULY 17, 2022
Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. It has to persuade patients to sign up for some heinous side effects. When patients stop taking Wegovy, their appetite returns within weeks, and they pack on weight. Its share price has risen 26 percent in the past year.
Let's personalize your content